Lisa Licitra

Learn More
Head and neck squamous cell carcinoma (HNSCC) is a disease with heterogeneous clinical behavior and response to therapies. Despite the introduction of multimodality treatment, 40-50% of patients with advanced disease recur. Therefore, there is an urgent need to improve the classification beyond the current parameters in clinical use to better stratify(More)
BACKGROUND The past three decades have seen rapid improvements in the diagnosis and treatment of most cancers and the most important contributor has been research. Progress in rare cancers has been slower, not least because of the challenges of undertaking research. SETTINGS The International Rare Cancers Initiative (IRCI) is a partnership which aims to(More)
The integration of chemotherapy and radiotherapy for the treatment of advanced head and neck cancer is still a matter of clinical investigation. An important limitation is that the concomitant administration of chemotherapy and radiotherapy still induces severe toxicity. In this paper, a simple artificial neural network is used to predict, on the basis of(More)
(2015) The impact of colleague peer review on the radiotherapy treatment planning process in the radical treatment of lung cancer. The CEA second-look trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ Open 4(5): e004385. Sir, We have read with considerable interest the case-control(More)
An increasing prevalence of chronic diseases is observed, among which cancer is now included because of its survival rates. That trend requires new ways of supporting outpatients and improving their compliance to treatments. This paper introduces HeNeA, a mobile application designed to support patients affected by Head and Neck cancer during their(More)
  • 1